Johnson & Johnson (JNJ)

One of J&J's investments stands head-and-shoulders above the rest.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Looking for a dividend stock you can sleep well owning? Here's why Johnson & Johnson could be the long-term healthcare anchor your portfolio needs.

The company's autoimmune drug was approved for the treatment of a rare blood disease.

The company is firing on all cylinders.

Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.

These two high-quality dividend payers have had very different fortunes recently.

American States Water has quietly been increasing its dividend for over 70 years.

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

Both of these healthcare leaders are Dividend Kings.

Bear markets are a normal part of investing, so you should always own some stocks that are resilient to market downturns.

All three are also solid "forever" holdings, but the next five years could be particularly exciting as each company bounces back from recent challenges.

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.